221 related articles for article (PubMed ID: 32446360)
1. Exploring the potential of engineered exosomes as delivery systems for tumor-suppressor microRNA replacement therapy in ovarian cancer.
Kobayashi M; Sawada K; Miyamoto M; Shimizu A; Yamamoto M; Kinose Y; Nakamura K; Kawano M; Kodama M; Hashimoto K; Kimura T
Biochem Biophys Res Commun; 2020 Jun; 527(1):153-161. PubMed ID: 32446360
[TBL] [Abstract][Full Text] [Related]
2. The hypoxia-related microRNA miR-199a-3p displays tumor suppressor functions in ovarian carcinoma.
Kinose Y; Sawada K; Nakamura K; Sawada I; Toda A; Nakatsuka E; Hashimoto K; Mabuchi S; Takahashi K; Kurachi H; Lengyel E; Kimura T
Oncotarget; 2015 May; 6(13):11342-56. PubMed ID: 25839163
[TBL] [Abstract][Full Text] [Related]
3. Omental cancer-associated fibroblast-derived exosomes with low microRNA-29c-3p promote ovarian cancer peritoneal metastasis.
Han Q; Tan S; Gong L; Li G; Wu Q; Chen L; Du S; Li W; Liu X; Cai J; Wang Z
Cancer Sci; 2023 May; 114(5):1929-1942. PubMed ID: 36644823
[TBL] [Abstract][Full Text] [Related]
4. miR-199a-3p enhances cisplatin sensitivity of ovarian cancer cells by targeting ITGB8.
Cui Y; Wu F; Tian D; Wang T; Lu T; Huang X; Zhang P; Qin L
Oncol Rep; 2018 Apr; 39(4):1649-1657. PubMed ID: 29436681
[TBL] [Abstract][Full Text] [Related]
5. Exosomes from human-bone-marrow-derived mesenchymal stem cells protect against renal ischemia/reperfusion injury via transferring miR-199a-3p.
Zhu G; Pei L; Lin F; Yin H; Li X; He W; Liu N; Gou X
J Cell Physiol; 2019 Dec; 234(12):23736-23749. PubMed ID: 31180587
[TBL] [Abstract][Full Text] [Related]
6. MiR-199a/b-3p inhibits gastric cancer cell proliferation via down-regulating PAK4/MEK/ERK signaling pathway.
Zeng B; Shi W; Tan G
BMC Cancer; 2018 Jan; 18(1):34. PubMed ID: 29304764
[TBL] [Abstract][Full Text] [Related]
7. Potential of peptide-engineered exosomes with overexpressed miR-92b-3p in anti-angiogenic therapy of ovarian cancer.
Wang J; Wang C; Li Y; Li M; Zhu T; Shen Z; Wang H; Lv W; Wang X; Cheng X; Xie X
Clin Transl Med; 2021 May; 11(5):e425. PubMed ID: 34047469
[TBL] [Abstract][Full Text] [Related]
8. Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer.
Kanlikilicer P; Bayraktar R; Denizli M; Rashed MH; Ivan C; Aslan B; Mitra R; Karagoz K; Bayraktar E; Zhang X; Rodriguez-Aguayo C; El-Arabey AA; Kahraman N; Baydogan S; Ozkayar O; Gatza ML; Ozpolat B; Calin GA; Sood AK; Lopez-Berestein G
EBioMedicine; 2018 Dec; 38():100-112. PubMed ID: 30487062
[TBL] [Abstract][Full Text] [Related]
9. Targeted delivery of microRNA-199a-3p using self-assembled dipeptide nanoparticles efficiently reduces hepatocellular carcinoma in mice.
Varshney A; Panda JJ; Singh AK; Yadav N; Bihari C; Biswas S; Sarin SK; Chauhan VS
Hepatology; 2018 Apr; 67(4):1392-1407. PubMed ID: 29108133
[TBL] [Abstract][Full Text] [Related]
10. Suppressing miR-199a-3p by promoter methylation contributes to tumor aggressiveness and cisplatin resistance of ovarian cancer through promoting DDR1 expression.
Deng Y; Zhao F; Hui L; Li X; Zhang D; Lin W; Chen Z; Ning Y
J Ovarian Res; 2017 Jul; 10(1):50. PubMed ID: 28743276
[TBL] [Abstract][Full Text] [Related]
11. Exosome-mediated delivery of functionally active miRNA-142-3p inhibitor reduces tumorigenicity of breast cancer in vitro and in vivo.
Naseri Z; Oskuee RK; Jaafari MR; Forouzandeh Moghadam M
Int J Nanomedicine; 2018; 13():7727-7747. PubMed ID: 30538455
[TBL] [Abstract][Full Text] [Related]
12. Exosomal miR-99a-5p is elevated in sera of ovarian cancer patients and promotes cancer cell invasion by increasing fibronectin and vitronectin expression in neighboring peritoneal mesothelial cells.
Yoshimura A; Sawada K; Nakamura K; Kinose Y; Nakatsuka E; Kobayashi M; Miyamoto M; Ishida K; Matsumoto Y; Kodama M; Hashimoto K; Mabuchi S; Kimura T
BMC Cancer; 2018 Nov; 18(1):1065. PubMed ID: 30396333
[TBL] [Abstract][Full Text] [Related]
13. miR-199a-3p targets stemness-related and mitogenic signaling pathways to suppress the expansion and tumorigenic capabilities of prostate cancer stem cells.
Liu R; Liu C; Zhang D; Liu B; Chen X; Rycaj K; Jeter C; Calhoun-Davis T; Li Y; Yang T; Wang J; Tang DG
Oncotarget; 2016 Aug; 7(35):56628-56642. PubMed ID: 27447749
[TBL] [Abstract][Full Text] [Related]
14. Engineering exosomes derived from subcutaneous fat MSCs specially promote cartilage repair as miR-199a-3p delivery vehicles in Osteoarthritis.
Zhao S; Xiu G; Wang J; Wen Y; Lu J; Wu B; Wang G; Yang D; Ling B; Du D; Xu J
J Nanobiotechnology; 2023 Sep; 21(1):341. PubMed ID: 37736726
[TBL] [Abstract][Full Text] [Related]
15. Exosomes derived from microRNA-199a-overexpressing mesenchymal stem cells inhibit glioma progression by down-regulating AGAP2.
Yu L; Gui S; Liu Y; Qiu X; Zhang G; Zhang X; Pan J; Fan J; Qi S; Qiu B
Aging (Albany NY); 2019 Aug; 11(15):5300-5318. PubMed ID: 31386624
[TBL] [Abstract][Full Text] [Related]
16. Plasma exosomal miR-199a-3p downregulates cell proliferation and migration in Hirschsprung's disease by targeting mTOR.
Daiyue Y; Yang Y; Zhaorong H; Yi L; Chen W; Caiyun L; Yuqian S; Liucheng Y; Kai W
Pediatr Surg Int; 2022 Dec; 39(1):54. PubMed ID: 36534156
[TBL] [Abstract][Full Text] [Related]
17. circ-CSPP1 promotes proliferation, invasion and migration of ovarian cancer cells by acting as a miR-1236-3p sponge.
Li QH; Liu Y; Chen S; Zong ZH; Du YP; Sheng XJ; Zhao Y
Biomed Pharmacother; 2019 Jun; 114():108832. PubMed ID: 30965236
[TBL] [Abstract][Full Text] [Related]
18. MiR-574-3p exerts as a tumor suppressor in ovarian cancer through inhibiting MMP3 expression.
Zheng J; Zhou Y; Li XJ; Hu JM
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6839-6848. PubMed ID: 31486483
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-199a-3p regulates endometrial cancer cell proliferation by targeting mammalian target of rapamycin (mTOR).
Wu D; Huang HJ; He CN; Wang KY
Int J Gynecol Cancer; 2013 Sep; 23(7):1191-7. PubMed ID: 23851675
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-223-3p Regulates Ovarian Cancer Cell Proliferation and Invasion by Targeting SOX11 Expression.
Fang G; Liu J; Wang Q; Huang X; Yang R; Pang Y; Yang M
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28587313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
